The drugs crizotinib and lorlatinib have the potential to be new treatments for various forms of breast cancer. Professor Lord and his team will be investigating how these drugs work and using that information to work out the best way to use them to benefit patients.

Professor Nicholas Turner and Dr Alicia Okines will lead a clinical trial of the drug crizotinib for patients with lobular breast cancer that has spread to other parts of the body. This trial, called the ROLO study, could lead to a much-needed new treatment for this type of breast cancer.

Breast cancer stem cells are likely to be the reason why some breast cancers manage to avoid treatment, come back and spread. Dr Ucar aims to investigate whether stopping two proteins from working in breast cancer stem cells could offer a way to target and destroy the cells.

 

Professor Lewis will investigate whether targeting two molecules, CXCR4 and VEGFA, can prevent relapse and the development of secondary tumours in triple negative breast cancer.

 

Dr Georgia Mavria is studying how a molecule called DOCK4 is involved in the spread of breast cancer to the brain. Her work could lead to new ways to prevent secondary tumours from growing in the brain and ultimately save lives.

 

The Breast Cancer Now LEGACY Study is the first research project of this kind dedicated to secondary breast cancer to be conducted in the UK.